Skip to content

D&A at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$2B+13.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$123.2M-2.9%
Glaukos logo
GlaukosGKOS
$2.91M+9.7%
Bausch + Lomb logo
Bausch + LombBLCO
$101M-4.7%
HRO
HarrowHROW
$455K-2.2%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$636K+28.0%

Other financials

Income statement

See full
Operating income-$15.4M-108%
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$744.23M-23.4%
Enterprise value$506.93M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Schering-Plough’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schering-Plough's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schering-Plough's D&A?
Schering-Plough (SGP) reported D&A of $153K in Q4 2025.
How has Schering-Plough's D&A changed year-over-year?
Schering-Plough's D&A increased by 125.8% year-over-year, from $67.75K to $153K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.